Masimo Sues US Customs Over Apple Watch Import Approval
PorAinvest
viernes, 22 de agosto de 2025, 1:53 pm ET1 min de lectura
AAPL--
The lawsuit comes just days after Apple Inc. announced it would reintroduce the blood-oxygen reading feature to its smartwatches, following a ruling from U.S. Customs and Border Protection. Masimo argues that CBP exceeded its authority by creating what it calls "loopholes" in an existing International Trade Commission (ITC) exclusion order that had blocked imports of Apple's Series 9 and Ultra 2 watches due to patent infringement [2].
Masimo has accused Apple of poaching employees and stealing trade secrets to integrate the feature into the Apple Watch, and has multiple lawsuits pending against Apple for patent infringement and trade secret theft. Apple has continued to sell redesigned watches in the U.S. without the blood-oxygen function, while unaffected models remained available internationally [2].
The lawsuit is the latest in a series of legal battles between the two companies, with Masimo seeking to block the CBP ruling and reinstate the block on Apple Watches with blood-oxygen tracking. Apple's stock dropped 1.97% during regular trading and slipped an additional 0.18% in after-hours trading following the lawsuit [2].
References:
[1] https://macdailynews.com/2025/08/21/masimo-sues-u-s-customs-and-border-protection-over-apple-watch-import-approval/
[2] https://www.benzinga.com/markets/tech/25/08/47252149/apple-restores-blood-oxygen-tracking-to-watch-after-customs-ruling-masimo-strikes-back-with-lawsuit-over-patent-rights
MASI--
Masimo has filed a lawsuit against U.S. Customs over the approval of importing Apple Watches with blood oxygen monitoring features. The lawsuit challenges a decision that allows Apple to bypass an import ban imposed by the U.S. International Trade Commission. The move highlights ongoing tensions between the two companies over patent rights, with Masimo shares falling 1.1% in early U.S. trading.
Masimo Corp. has filed a lawsuit against U.S. Customs and Border Protection (CBP) in Washington, D.C., federal court, challenging the agency's decision to approve the import of Apple Watches equipped with blood-oxygen monitoring technology. The move comes amidst an ongoing patent dispute between the two companies, with Masimo alleging that CBP wrongly reversed its prior ruling from last year, which had restricted such imports, without notifying Masimo or justifying the change [1].The lawsuit comes just days after Apple Inc. announced it would reintroduce the blood-oxygen reading feature to its smartwatches, following a ruling from U.S. Customs and Border Protection. Masimo argues that CBP exceeded its authority by creating what it calls "loopholes" in an existing International Trade Commission (ITC) exclusion order that had blocked imports of Apple's Series 9 and Ultra 2 watches due to patent infringement [2].
Masimo has accused Apple of poaching employees and stealing trade secrets to integrate the feature into the Apple Watch, and has multiple lawsuits pending against Apple for patent infringement and trade secret theft. Apple has continued to sell redesigned watches in the U.S. without the blood-oxygen function, while unaffected models remained available internationally [2].
The lawsuit is the latest in a series of legal battles between the two companies, with Masimo seeking to block the CBP ruling and reinstate the block on Apple Watches with blood-oxygen tracking. Apple's stock dropped 1.97% during regular trading and slipped an additional 0.18% in after-hours trading following the lawsuit [2].
References:
[1] https://macdailynews.com/2025/08/21/masimo-sues-u-s-customs-and-border-protection-over-apple-watch-import-approval/
[2] https://www.benzinga.com/markets/tech/25/08/47252149/apple-restores-blood-oxygen-tracking-to-watch-after-customs-ruling-masimo-strikes-back-with-lawsuit-over-patent-rights

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios